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Anaplastic lymphoma kinase (ALK) constitutes a part
of the oncogenic fusion proteins nucleophosmin-ALK
and echinoderm microtubule–associated protein like
4–ALK, which are aberrantly expressed in a subset of
T-cell anaplastic large-cell lymphoma and non–small-
cell lung cancer, respectively. The expression of mu-
tated, constitutively active ALK also occurs in a subset
of neuroblastoma tumors. ALK is believed to play an
important role in promoting tumor survival. Never-
theless, the mechanisms underlying the expression
of ALK in cancer cells are not completely known.
MicroRNA (miR) has been implicated in the regula-
tion of the expression of both oncogenes and tumor
suppressor genes. We tested the hypothesis that the
expression of ALK could be regulated by miR. Three
Internet-based algorithms identified miR-96 to poten-
tially bind with the ALK 3=-untranslated region. Nota-
bly, miR-96 levels were markedly decreased in ALK-
expressing cancer cell lines and primary human
tumors compared with their normal cellular and tis-
sue counterparts. Transfection of the cell lines with
miR-96 decreased levels of the different forms of ALK
protein, without significant effects on ALK mRNA.
Furthermore, miR-96 decreased the phosphorylation
of ALK target proteins, including Akt, STAT3, JNK, and
type I insulin-like growth factor receptor, and it
down-regulated JunB. These effects were associated
with reduced proliferation, colony formation, andmi-
1772gration of ALK-expressing cancer cells. These data
provide novel evidence that decreases in miR-96
could represent a mechanism underlying the aber-
rant expression of ALK in cancer cells. (Am J Pathol
2012, 180:1772–1780; DOI: 10.1016/j.ajpath.2012.01.008)
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine
kinase with structural similarities to members of the insu-
lin receptor superfamily, which includes type I insulin-like
growth factor (IGF-I), c-Met, and leukocyte tyrosine ki-
nase receptors.1 The physiological expression of ALK is
largely limited to neural cells at an early developmental
stage. In addition, ALK is aberrantly expressed as a
part of the oncogenic protein nucleophosmin (NPM)–
ALK in 60% of the T-cell anaplastic large-cell lym-
phoma cases that harbor the chromosomal transloca-
tion t(2;5)(p23;q35).2,3 The recent discovery of the
chimeric protein, echinoderm microtubule–associated
protein like 4 (EML4)–ALK, that associates the
inv(2)(p21p23) chromosomal abnormality, identified in
5% to 7% of non–small-cell lung cancer (NSCLC)
cases, and the activating mutations of ALK in familial
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ALK in human malignancies.4–8 It is believed that ALK
plays an important role in these malignancies by promot-
ing the survival and proliferation and inhibiting the apop-
tosis of the neoplastic cells.9 The oncogenic effects of
ALK appear to be related to its ability to interact with and
activate, through phosphorylation, several important sur-
vival-promoting transcription factors and protein kinases,
including STAT3, phosphatidylinositol 3-kinase/Akt, mito-
gen-activated protein kinase, and IGF-I receptor (IGF-
IR).10–15 Therefore, ALK inhibitors are being tested in
clinical trials that include patients with ALK-expressing
(ALK) tumors with the hope that targeting ALK will even-
tually transform into an effective strategy to eradicate
these aggressive types of cancer.16–19 Intriguingly, the
mechanisms that contribute to the aberrant expression of
ALK in cancer cells are not completely known. Although
translocations and inversions involving the ALK gene on
chromosome 2p23 are considered to be one mecha-
nism,2,20 these chromosomal abnormalities are most likely
not the only factor. In agreement with this idea, transloca-
tions and inversions involving ALK do not exist in tumors in
which full-length or mutated ALK is aberrantly expressed.
MicroRNAs (miRNAs) form a class of small, noncod-
ing, regulatory RNAs that bind to the 3=-untranslated re-
gion (UTR) of target mRNA, resulting in its degradation or
translational inhibition. Deregulation of miRNA occurs in
cancer, and certain miRNAs function as oncogenes or
tumor suppressor genes.21–24 We reasoned that one pos-
sible mechanism for the up-regulation of ALK expression
in cancer cells could be mediated through deregulated
expression of miRNA.
Materials and Methods
Potential Targets of miRNA
Analysis of miRNA-predicted targets was performed by
using three different Internet-based algorithms: Target-
Scan (http://www.targetscan.org, last accessed March
14, 2012), miRanda (http://www.microrna.org/microrna/
home.do, last accessed March 14, 2012), and PicTar
(http://pictar.mdc-berlin.de, last accessed March 14,
2012).
Antibodies
Antibodies to phosphorylated ALK (pALK, Tyr1604;
3341), pSTAT3 (Tyr705; 9131), pIGF-IR (Tyr1131; 3021),
Akt (9272), pAkt (Ser473; 4051), JNK (3708s), pJNK
(Thr183/Tyr185; 4668), and JunB (3753) were obtained
from Cell Signaling Technology (Danvers, MA). IGF-
IR (39–6700) was obtained from Zymed Laboratories
(South San Francisco, CA), ALK (M7195) was obtained
from Dako (Carpinteria, CA), STAT3 (sc-8019) was ob-
tained from Santa Cruz Biotechnology (Santa Cruz,
CA), and -actin (A-2228) was obtained from Sigma (St
Louis, MO).Cell Lines and Human Tissue Specimens
The NPM-ALK–expressing (NPM-ALK) T-cell lymphoma
cell lines Karpas 299, SUP-M2, SU-DHL-1, SR-786, and
DEL were obtained from DSMZ (Braunschweig, Ger-
many). The NSCLC cell line H2228, which expresses
EML4-ALK; the neuroblastoma cell line SH-SY5Y, which
expresses ALK with the somatic activating mutation
F1174L (ALKF1174L); and the human embryonic kidney
cell line 293T were obtained from American Type Culture
Collection (Manassas, VA). Control human cells used in
the study included normal human T lymphocytes (Stem-
cell Technologies, Vancouver, BC, Canada), the human
lung epithelial cells BEAS-2B (American Type Culture
Collection), and the human brain neural cells HCN-1A
(American Type Culture Collection). Cell lines were main-
tained in RPMI 1640 medium (Karpas 299, SUP-M2, SU-
DHL-1, SR-786, DEL, and H2228), minimal essential me-
dium (SH-SY5Y), or Dulbecco’s modified Eagle’s medium
(HCN-1A and 293T), supplemented with 10% fetal bovine
serum (Sigma), 2 mmol/L glutamine, 100 U/mL penicillin,
and 100 g/mL streptomycin at 37°C in humidified air
with 5% CO2. The BEAS-2B cells were maintained in
bronchial epithelial cell growth medium, with all supple-
ments as provided by the manufacturer (Lonza, Allen-
dale, NJ).
The expression of miR-96 was also analyzed in archi-
val formalin-fixed, paraffin-embedded (FFPE) tissue sec-
tions from five patients with ALK T-cell lymphoma and
four patients with EML4-ALK NSCLC. The expression of
ALK was established based on immunohistochemical
staining in all tumors. In addition, EML4-ALK expression
was confirmed by fluorescence in situ hybridization anal-
ysis. Three reactive lymph nodes and two normal lung
tissues were used as controls. Approval of the institu-
tional ethical committee was secured before the initiation
of these studies.
Transfection of miRNA and Plasmids
The RNA mimic for miR-96 and the control mimic miRNA
(cel-miR-67; developed from Caenorhabditis elegans with
no sequence identity with human miRNA) were obtained
from Dharmacon (Lafayette, CO). Electroporation and the
Nucleofector V solution were used (A-030 program;
Amaxa Biosystems, Basel, Switzerland) to transfect the
NPM-ALK T-cell lymphoma cell lines with miRNA or
plasmids. Transfection of H2228, SH-SY5Y, and 293T
cells was performed by using DharmaFECT Duo trans-
fection reagent (Dharmacon) or Lipofectamin 2000 (Invit-
rogen, Carlsbad, CA).
Plasmids, Cloning, and Luciferase Assay
To induce the expression of wild-type (WT) NPM-ALK
protein, portions of NPM-ALK were amplified by PCR
using the following primers: NPM-ALK-Forward: 5=-GC-
GAAGCTTATGGAAGATTCGATGGACAT-3= (bearing
HindIII cassette), and NPM-ALK-Reverse: 5=-AGTCTC-
GAGTCAGGGCCCAGGCTGGTTCATG-3= (bearing XhoI
cassette). The PCR product subsequently was digested
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(Invitrogen). To induce the expression of NPM-ALK pro-
tein with the 3=-UTR region containing the miR-96 binding
site, two sets of primers were used in 3 PCR reactions. In
the first reaction, NPM-ALK-Forward (F1): 5=-GCGAAG-
CTTATGGAAGATTCGATGGACAT-3= (bearing HindIII
cassette) and NPM-ALK-3=-UTR-Reverse (R1): 5=-GAC-
CGAGCTCAGGGCCCAGGCT-3= were used, and in the
second reaction, NPM-ALK-3=-UTR-Forward (F2): 5=-
AGCCTGGGCCCTGAGCTCGGTC-3=; NPM-ALK-3=-UTR-
Reverse (R2): 5=-GTGCTCGAGAGTCATTACAAATAACT-
CC-3= (bearing XhoI cassette) were used. Finally, in the
third PCR reaction, F1 and R2 primers were used to
generate the final product that contains NPM-ALK with
3=-UTR. The PCR product was subsequently digested
with HindIII/XhoI and subcloned into pCDNA4.0 vector.
Positive clones were confirmed by sequencing.
For the luciferase assay experiments, human ALK 3=-
UTR (454 bp) was amplified from genomic DNA using the
following primers: ALK-3=-UTR-Forward: 5=-AGTTCTA-
GAATGAACCAGCCTGGGCCCTGAGCTCG-3= (bearing
XbaI cassette), ALK-3=-UTR-Reverse: 5=-AGTTCTAGAA-
GTCATTACAAATAACTCCTTTATTTC-3= (bearing XbaI
cassette), cloned in XbaI site of pGL3-control vector (Pro-
mega, Madison, WI), and designated as pGL3-control-
WT-ALK-3=-UTR. Also, ALK mutated at 3=-UTR (original
sequence: 5=-GTCACGTTTTGTTTTGTGCCAAC-3=; se-
quence after mutation: 5=-GTCACGTTTTGTTTTGTAAC-
3=) was generated by using site directed mutagenesis
and a commercially available kit (200523, Agilent Tech-
nologies, Santa Clara, CA). Primers used for PCR ampli-
fication of mutated ALK 3=-UTR were: Forward: 5=-T-
AGTCAGTTGACGAAGATCTGGTCAAGAACTAATTAAA-
TGTTTCATT-3=; and Reverse: 5=-AATGAAACATTTAAT-
TAGTTCTTGACCAGATCTTCGTCAACTGACTA-3=. The
293T cells were transfected with empty vector (pGL3-
control vector, Promega), WT ALK (pGL3-WT-ALK-3=-
UTR) or mutated (MUT) ALK (pGL3-MUT-ALK-3=-UTR) for
48 hours. Renilla luciferase activity was measured by
using DualGlo Luciferase assay system (Promega).
qPCR Analysis
Total RNA was extracted according to the manufacturer’s
instructions (Qiagen, Valencia, CA). The relative level of
miRNA was determined by quantitative real-time PCR
(qPCR) using specific primers according to the TaqMan
miRNA assay protocol (Applied Biosystems, Foster City,
CA). To measure miRNA levels in FFPE tissue sections
prepared from tissue specimens, the High Pure FFPE
RNA Micro Kit (Roche Applied Science, Indianapolis, IN)
was used, according to the manufacturer’s protocol. After
isolation of total RNA, complementary DNA was synthe-
sized by using the TaqMan miRNA RT-PCR Kit (Applied
Biosystems). The miRNAs were amplified individually and
in duplicate. The relative level of individual miRNA with
reference to the small nucleolar RNA RNU48 (Applied
Biosystems) was calculated using the CT method. For
ALK cDNA synthesis, 300 ng of total RNA was reverse
transcribed using random primers and SuperScript II
Reverse Transcriptase (Invitrogen). NPM-ALK, EML4-ALK, and ALK mRNAs were quantified by the TaqMan
qPCR kit (Applied Biosystems) and normalized to the
ribosomal RNA 18S. Each sample in the PCR assay in-
cluded 12.5 L of TaqMan Universal Master Mix No
Amperase UNG (2), 1.15 L of 20 times Assays-on-
Demand Gene Expression Assay Mix, 10.35 L of nu-
clease-free H2O, and 1.0 L of cDNA diluted in RNase-
free water, in a final volume of 25 L. All qPCR tests were
performed by using the Applied Biosystems 7500 Se-
quence Detection System. The PCR thermal cycling con-
ditions were as follows: 10 minutes at 95°C for AmpliTaq
Gold activation and 45 cycles for the melting (95°C, 15
seconds) and annealing/extension (60°C, 1 minute)
steps. The CT data were determined using default thresh-
old settings.
Measurement of Cell Proliferation by
BrdU Assay
Cell lines were transfected with control mimic or miR-96,
and cell proliferation was measured using the 5-bromo-
2=-deoxyuridine (BrdU) assay kit (ExAlpha, Shirley, MA),
according to the manufacturer’s instructions. Briefly, 2 
105 cells/mL were plated into a 96-well plate. The BrdU
label (1:500 dilution) was added, and the plate was in-
cubated for 24 hours at 37°C. Cells were then fixed for 30
minutes at room temperature. The anti-BrdU antibody
was added for 1 hour after washing, followed by peroxi-
dase goat anti-mouse IgG conjugate (1:2000 dilution)
for 30 minutes. Thereafter, the 3,3=,5,5=-tetramethyl-
benzidine peroxidase substrate was added and incu-
bated for 30 minutes at room temperature in the dark. The
plate was read at 450 nm using an ELISA plate reader
after adding the stop solution. Experiments were per-
formed in triplicate.
Methylcellulose Colony Assay
The methylcellulose medium was prepared by mixing
1.0% methylcellulose stock (Methocult H4230; Stem-
cell Technologies) with RPMI 1640 medium, prepared
as previously described, in a 1:5 ratio. Then, 3.5 mL of
methylcellulose was added to 15-mL tubes. Cells were
resuspended to eliminate clumping and then added in
a 1:10 (v/v) ratio to the methylcellulose. Tubes were
tightly capped, and the mix was gently inverted several
times. Then, 500 L of the mix was divided into humid-
ified 6-well plates in triplicate. Plates were placed in a
humidified incubator at 37°C in 5% CO2 for 5 days and
then p-iodonitrotetrazolium violet was added for
48 hours. Colonies were visualized using Alexfluor
(Invitrogen).
Cell Migration Assay
Untreated cells or cells transfected with negative control
mimic or miR-96 for 48 hours were washed with PBS and
resuspended in serum-free medium. Thereafter, 0.6 mL
of serum-free medium, with or without 500 ng/mL IGF-I
(R&D Systems, Minneapolis, MN), was added to the bot-
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Scientific, Pittsburgh, PA), followed by the addition of 0.1
mL of transfected cells into the top compartment. Plates
were incubated for 4 hours at 37°C. Cells migrating
through the membrane into the lower chamber were
counted using a particle counter and size analyzer
(Coulter, Indianapolis, IN).
Western Blot Analysis
Cell lysates were collected using standard techniques,
as previously described.15,25 The lysis buffer contained
25 mmol/L HEPES (pH 7.7), 400 mmol/L NaCl, 1.5 mmol/L
MgCl2, 2 mmol/L EDTA, 0.5% Triton X-100, 0.1 mmol/L
phenylmethylsulfonyl fluoride, 3 mmol/L dithiothreitol,
phosphatase inhibitor cocktail (20 mmol/L -glycerol
phosphate and 1 mmol/L Na3VO4; Roche Applied Sci-ence), and protease inhibitor cocktail (10 g/mL leupep-
tin, 2 g/mL pepstatin, 50 g/mL antipain, 1 benzami-
dine, 2 g/mL aprotinin, and 20 g/mL chymostatin;
Roche Applied Science). For Western blot analysis, 50 to
80 g of total proteins was electrophoresed on 8% SDS-
PAGE. The proteins were transferred to nitrocellulose
membranes, probed with specific primary antibodies,
and then probed with the appropriate secondary antibod-
ies. Proteins were detected using a chemiluminescence-
based kit (GE Healthcare, Piscataway, NJ).
Statistical Analysis
The Student’s t-test for paired data was used. P  0.05
Figure 1. A: Sequence alignment shows poten-
tial binding sites between miR-96 seed sequence
and ALK 3=-UTR. B: The qPCR analysis demon-
strates that the endogenous expression of
miR-96 is markedly decreased in the NPM-ALK
T-cell lymphoma cell lines Karpas 299, SUP-M2,
SU-DHL-1, SR-786, and DEL. In contrast, a re-
markably higher level of miR-96 is seen in the
normal human T lymphocytes (P  0.0001). C:
The NSCLC cell line, H2228, and the neuroblas-
toma cell line, SH-SY5Y, which express EML4-
ALK and ALKF1174L proteins, respectively, ex-
press negligible amounts of miR-96 compared
with the control cell lines: the normal human
lung epithelial cells, BEAS-2B, and the normal
human neural brain cells, HCN-1A (P  0.0001
and P  0.0007), respectively. D and E: The
levels of ALK mRNA are markedly increased in
the ALK cancer cell lines when compared with
normal human T-lymphocyte and the HCN-1A
(D) and the BEAS-2B (E) cell lines. *P  0.05,
†P  0.01, ‡P  0.0001 compared with the cor-
responding normal cellular counterparts. F: The
qPCR analysis shows that the expression of
miR-96 is significantly decreased in five human
primary ALK T-cell lymphoma tumors com-
pared with three reactive lymph nodes. P 
0.0003. LN, lymph node; Pt, patient. G: miR-96 is
markedly decreased in four EML4-ALK NSCLC
primary tumors compared with two normal hu-
man lung tissues. P  0.007. The results repre-
sent the mean  SE of three different experi-
ments, performed in triplicate, with consistent
results.was considered statistically significant.
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Potential Binding Sites between miR-96 and
ALK 3=-UTR
We used three different miRNA-target prediction algo-
rithms, and all of them identified miR-96 as an miRNA that
can potentially bind with ALK 3=-UTR. The binding sites
between miR-96 and ALK 3=-UTR are shown in Figure 1A.
miR-96 is Markedly Decreased in Cancer Cell
Lines and Primary Human Tumors that
Aberrantly Express the Different Forms of ALK
Protein
We used qPCR analysis to measure the levels of miR-96
in human ALK cancer cell lines. Compared with normal
human T lymphocytes, the level of miR-96 was markedly
reduced in the T-cell lymphoma cell lines that express
NPM-ALK (Figure 1B). miR-96 was also decreased in the
NSCLC cell line H2228, which expresses EML4-ALK,
compared with the normal human lung epithelium cell line
BEAS-2B, and in the neuroblastoma cell line SH-SY5Y,
which expresses ALKF1174L, compared with normal hu-
man neural brain cells HCN-1A (Figure 1C). Conversely,
the ALK cancer cell lines expressed much higher levels
of ALK mRNA compared with the normal cellular coun-
terparts (Figure 1, D and E). Similar to the cell lines, miR-96
was remarkably decreased in ALK T-cell lymphoma tu-
mors compared with reactive lymph nodes (Figure 1F). Fur-
thermore, miR-96 was significantly decreased in EML4-
ALK NSCLC tumors compared with normal lung tissues
(Figure 1G).
Interactions between miR-96 and ALK 3=-UTR
To examine whether miR-96 interacts with ALK 3=-UTR,
we used a luciferase assay analysis in 293T cells that
showed that miR-96 suppresses the luciferase activity
driven by ALK 3=-UTR, not the luciferase activity driven by
ALK mutated at 3=-UTR (Figure 2A). Furthermore, 293T
cells transfected with NPM-ALK plasmid associated with
its 3=-UTR or, alternatively, with NPM-ALK plasmid that
lacks the 3=-UTR, were cotransfected with miR-96. There-
after, Western blot studies showed that miR-96 induced a
marked decrease in the NPM-ALK-3=-UTR construct, not
in the NPM-ALK construct that lacked 3=-UTR (Figure 2B).
Transfection of miR-96 Decreases Levels of the
Different Forms of ALK Protein, and Down-
Regulation of the ALK Proteins Enhances the
Expression of miR-96
Transfection of Karpas 299 and SUP-M2 with miR-96
induced a substantial decrease in NPM-ALK protein lev-
els at 48 hours after transfection (Figure 3A). Further-
more, miR-96 also efficiently decreased the levels of
EML4-ALK and ALKF1174L proteins in the H2228 and SH-
SY5Y cell lines, respectively (Figure 3A). Transfection ofmiR-96 did not induce significant change in ALK mRNA
(data not shown). The decrease in the different forms of
ALK protein was associated with a remarkable down-
regulation of their phosphorylated forms, which was also
associated with a marked decrease in the phosphoryla-
tion levels of ALK oncogenic target proteins, including
Akt, STAT3, JNK, and IGF-IR. Similar changes were not
detected in the basal levels of Akt, STAT3, JNK, or IGF-IR
(Figure 3A). The decrease in ALK was also associated
with a marked decrease in JunB protein (Figure 3A).
These experiments were also performed in other NPM-
ALK T-cell lymphoma cell lines, with similar results
(data not shown). When the ALK proteins were effi-
ciently down-regulated by small-interfering RNA
Figure 2. A: The 293T cells were cotransfected with WT ALK or ALKmutated
at 3=-UTR (MUT ALK) simultaneously with miR-96 or control mimic cel-miR-
67. After 48 hours, firefly and Renilla luciferase activities were measured
using a dual-luciferase assay. The results represent firefly luciferase normal-
ized to Renilla luciferase. Although miR-96 induced a marked decrease in
luciferase activity of ALK with intact 3=-UTR (P  0.05), it failed to induce a
similar effect when the ALK 3=-UTR was mutated at its binding site with
miR-96 (P  0.77). Luciferase activity measured in control 293T cells trans-
fected with empty vector pGL3, WT ALK, or ALK mutated at 3=-UTR alone is
also depicted. The mean SE values of three different experiments, performed
in triplicate, are shown. B: NPM-ALK with 3=-UTR (pCDNA4-NPM-ALK-3=-UTR)
or NPM-ALK lacking its 3=-UTR (pCDNA4-NPM-ALK) was cotransfected into
293T cells with miR-96 or the control miRNA cel-miR-67, as indicated. After 48
hours, NPM-ALK protein levels were determined by using Western blot analysis.
miR-96 induced a significant decrease in NPM-ALK transfected with its 3=-UTR,
with no effect on the levels of NPM-ALK that lacks the 3=-UTR. Baseline expres-
sion levels of the empty vector pCDNA4, pCDNA4-NPM-ALK, and pCDNA4-
NPM-ALK-3=-UTR are illustrated. -Actin shows equal protein loading.(siRNA; Figure 3B), we detected a significant increase
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ing that ALK may induce reciprocal inhibitory effects
on the expression of miR-96 (Figure 3, C–E).
Transfection of miR-96 Decreases Proliferation,
Colony Formation, and Migration of ALK
Cancer Cells
Next, we used a BrdU assay to test the effect of miR-96
on the proliferation of the cancer cell lines that express
the different forms of ALK protein. When compared with
cells transfected with the negative control cel-miR-67,
Karpas 299, SUP-M2, H2228, and SH-SY5Y cell lines trans-
fected with miR-96 demonstrated significant decreases in
their proliferation (Figure 4A). In addition, Karpas 299 and
DEL cell lines transfected with miR-96 demonstrated a
marked decrease in their ability to form colonies in methyl-
cellulose (Figure 4B). Moreover, transfection of the ALK
cancer cell lines with miR-96 abrogated their migration in
response to IGF-I stimulation (Figure 4C).
Discussion
The regulatory mechanisms that lead to up-regulation or
down-regulation of oncogenic or anti-oncogenic proteins,
respectively, are not completely known. For instance,
ALK is a tyrosine kinase with a well-described oncogenic
potential.9 By excluding the early stage of human devel-
opment, during which ALK is primarily expressed in neu-
ronal cells, the expression of ALK is aberrant and essen-
tially limited to cancerous cells. Although chromosomal
abnormalities involving the ALK gene, such as t(2;5)(p23;
q35) and inv(2)(p21p23), seen in some cases of T-celllymphoma and NSCLC, respectively, contribute to the
aberrant expression of ALK,2,20 these abnormalities do
not exist in all types of ALK cancer cells. Therefore, it is
reasonable to assume that other mechanisms may con-
tribute to the aberrant expression of ALK.
In the present study, we sought to explore whether
ALK oncogenic tyrosine kinase is regulated by miRNA.
To predict miRNA that may regulate ALK expression, we
used a consensus approach by using three miRNA-tar-
get prediction algorithms. The three algorithms simulta-
neously identified miR-96 as an miRNA that contained a
potential binding site compatible with ALK 3=-UTR. Be-
cause this 3=-UTR region also exists in NPM-ALK and
EML4-ALK, we measured endogenous levels of miR-96 in
several cell lines that express different forms of ALK
protein. miR-96 expression levels in the NPM-ALK T-cell
lymphoma cell lines Karpas 299, SUP-M2, SU-DHL-1,
SR-786, and DEL were remarkably lower than the normal
human T lymphocytes. Similarly, the expression of
miR-96 was markedly decreased in the NSCLC cell line
H2228, which expresses EML4-ALK, and the neuroblas-
toma cell line SH-SY5Y, which expresses ALKF1174L,
compared with the normal human epithelial lung cells
BEAS-B2 and the normal human neural brain cells HCN-
1A, respectively.
The interactions between miR-96 and ALK 3=-UTR
were demonstrated when miR-96 down-regulated the lu-
ciferase activity of WT ALK and, in contrast, it failed to
induce a similar effect on an ALK construct with mutated
3=-UTR. To further confirm the specific nature of the in-
teractions between miR-96 and ALK 3=-UTR, we inserted
NPM-ALK containing or lacking the 3=-UTR into expres-
sion vector and cotransfected these constructs with miR-96
Figure 3. A: A Western blot shows that miR-96
down-regulates the expression of NPM-ALK in
Karpas 299 and SUP-M2, EML4-ALK in H2228,
and ALKF1174L in SH-SY5Y cell lines. Control
cells were transfected with cel-miR-67. The de-
crease in the different forms of ALK protein was
associated with a marked decrease in the corre-
sponding phosphorylated ALK protein, which
was also associated with a pronounced down-
regulation of pAkt, pSTAT3, pJNK, JunB, and
pIGF-IR. Changes were not seen in the basal
levels of Akt, STAT3, JNK, or IGF-IR proteins.
-Actin shows equal protein loading. The West-
ern blot studies were repeated four times with
consistent results. B: A Western blot shows that
siRNA induced a marked decrease in ALK pro-
tein levels in Karpas 299, SUP-M2, H2228, and
SH-SY5Y cell lines. -Actin shows equal protein
loading. C: The decrease of NPM-ALK by siRNA
in Karpas 299 and SUP-M2 cell lines was associ-
ated with a significant increase in miR-96 expres-
sion (P  0.001 and P  0.023, respectively,
compared with cells transfected with scrambled
siRNA). D and E: The decrease in EML4-ALK in
H2228 (D) and ALKF1174L in SH-SY5Y (E) cell
lines by ALK siRNA was also associated with a
marked increase in miR-96 levels (P  0.0008
and P  0.02, respectively). The mean  SE
values of three different experiments, performed
in triplicate, are shown.or control miRNA into 293T cells. Western blot studies
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3=-UTR was down-regulated by miR-96, further demonstrat-
ing the presence of an miR-96–specific target region within
the 3=-UTR of ALK. These results support the direct interac-
Figure 4. A: The BrdU assay demonstrates that miR-96 decreases the pro-
liferation of the different ALK neoplastic cell lines at 48 hours after trans-
fection. The proliferation of cells transfected with miR-96 is shown compared
with the proliferation of cells transfected with the negative control cel-miR-
67. The results represent the mean  SE of three different experiments,
performed in triplicate, with consistent findings. *P  0.05, †P  0.01 com-
pared with control cells. B: Although transfection of miR-96 abrogates Karpas
299 and DEL cell growth in methylcellulose, cel-miR-67 failed to induce
similar effects. The experiment was repeated three times, with similar results.
C:miR-96 significantly decreased IGF-I–stimulatedmigration of the ALK cancer
cell lines. *P  0.001 versus IGF-I  miR-96; †P  0.05 versus untreated cells;
**P 0.001 versus untreated cells and IGF-ImiR-96; ‡P 0.01 versus IGF-I
miR-96; §P  0.001 versus untreated cells. The results represent the mean  SE
of three different experiments, performed in triplicate.tions between miR-96 and ALK 3=-UTR.Next, we questioned whether miR-96 is involved in the
regulation of ALK expression. Karpas 299, SUP-M2,
H2228, and SH-SY5Y cell lines were transfected with
miR-96 or a negative control miRNA. miR-96 induced
marked down-regulation of NPM-ALK, EML4-ALK, and
ALKF1174L proteins. In contrast, similar changes were not
observed in NPM-ALK, EML4-ALK, or ALKF1174L mRNA
after transfection of miR-96 (data not shown). These data
suggest that miR-96 induces negative regulation of ALK
expression post-transcriptionally. When the different forms
of ALK protein were down-regulated by siRNA, there was a
marked increase in miR-96 levels, indicating that ALK ap-
pears to sustain its own expression by exerting a reciprocal
negative feedback loop that hinders the expression of miR-
96. This is an intriguing finding, and further studies are
required to characterize the mechanisms by which ALK
induces this effect.
The different activated forms of ALK protein are be-
lieved to play a central role in driving the oncogenic
signaling and inducing cellular transformation through
the phosphorylation/activation of important survival pro-
teins, including Akt, STAT3, and JNK, and up-regulating
the expression of JunB.3,4,9–14 Consistent with these ob-
servations, down-regulation of NPM-ALK, EML4-ALK, or
ALKF1174L by miR-96 substantially decreased their phos-
phorylated/activated forms, which was simultaneously
associated with decreased pSTAT3, pAkt, and pJNK lev-
els and decreased JunB levels. We have recently shown
that NPM-ALK can also activate/phosphorylate IGF-IR
oncogenic tyrosine kinase, which enhances the onco-
genic effects of NPM-ALK.15 In the present study, when
we used miR-96, we found not only that the down-regu-
lation of NPM-ALK but also the down-regulation of EML4-
ALK and ALKF1174L can induce a marked decrease in
pIGF-IR levels, providing novel evidence that the different
forms of ALK protein are effectively capable of phospho-
rylating IGF-IR tyrosine kinase, in a manner similar to their
effects on Akt, STAT3, and JNK. Notably, the basal levels
of Akt, STAT3, JNK, and IGF-IR remained unchanged
after transfection of miR-96, indicating that miR-96 had no
direct effect on these proteins and that the decrease in
their phosphorylation was secondary to the decrease in
ALK/pALK levels. However, transfection of miR-96 was
also associated with a decrease in JunB protein expres-
sion. Thus, we questioned whether JunB protein is a
direct target of miR-96. Nevertheless, searching the three
Internet-based algorithms did not lead to the identifica-
tion of potential binding sites between miR-96 and JunB
3=-UTR. Therefore, it is most likely that the decrease in
JunB levels after transfection of miR-96 was secondary to
the decrease in ALK protein.14 It is important to empha-
size that the decrease in pAkt, pSTAT3, pJNK, pIGF-IR,
and JunB after down-regulating ALK by miR-96 was as-
sociated with a significant decrease in cell viability,
growth in methylcellulose, and IGF-I–stimulated migration
of ALK cancer cell lines. The inhibitory effects of miR-96
on IGF-I–stimulated migration further support that the
IGF-I/IGF-IR signaling axis is functionally active in these
tumors and that this axis is interacting with ALK.15
Mutations in the seed region of miR-96 were previously
implicated in autosomal dominant, progressive hearing
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miR-96 potential to target mRNA. The previously reported
roles of miR-96 in cancer appear to be cancer cell type
dependent. For example, miR-96 decreased FOXO1 pro-
tein levels and, consequently, contributed to the survival
of breast cancer cells.27 Alternatively, a more recent
study28 showed that miR-96 induces tumor suppression
of pancreatic cancer cells by decreasing the expression
of KRAS. The latter findings are in line with our proposed
model in which miR-96 down-regulates the expression of
ALK and, therefore, decreases the proliferation, colony
formation, and migration of ALK cells. Similar to our
findings in miR-96, a recent study29 showed that the
expression of abelson murine leukemia viral oncogene
homolog 1 (ABL1) and breakpoint cluster region-abelson
murine leukemia viral oncogene homolog 1 (BCR-ABL1),
two kinases with some biological features that are com-
parable to ALK and NPM-ALK, was attributed to de-
creased miR-203 levels.
ALK has been recently highlighted as a potential ther-
apeutic target, and ALK small-molecule inhibitors are
being tested in clinical trials that include patients with
ALK malignant tumors.16–19 Although these inhibitors
may prove to be beneficial, the recent identification of
mutations or amplifications of ALK that demonstrate sig-
nificant resistance to ALK inhibitors stresses the impor-
tance of identifying alternative and, perhaps, more effec-
tive approaches to target ALK.30,31 Our findings illustrate
miR-96 as a novel mechanism for the suppression of ALK
expression and suggest that transfection of miR-96 could
represent an effective strategy to down-regulate ALK and
to eradicate ALK tumor cells.32–34
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